Viatris (VTRS) Total Liabilities (2019 - 2026)
Viatris (VTRS) posted quarterly Total Liabilities of $22.2 billion for Q1 2026, down 2.84% year-over-year from $22.8 billion in Q1 2025, and down 1.36% quarter-over-quarter from $22.5 billion in Q4 2025.
Viatris (VTRS) Total Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Liabilities history runs 8 years deep, the most recent figure standing at $22.2 billion for Q1 2026.
- In Q1 2026, Total Liabilities fell 2.84% year-over-year to $22.2 billion; the TTM figure through Mar 2026 stood at $22.2 billion (down 2.84% YoY), while the FY2025 annual figure was $22.5 billion, down 1.68% from the prior year.
- Total Liabilities for Q1 2026 stood at $22.2 billion, down from $22.5 billion in the prior quarter.
- The five-year high for Total Liabilities was $33.0 billion in Q1 2022, with the low at $22.2 billion in Q1 2026.
- The 5-year median for Total Liabilities is $27.2 billion (2023), against an average of $26.4 billion.
- Peak annual rise in Total Liabilities reached 1.68% in 2025, while the deepest fall reached 16.48% in 2025.
- Viatris' Total Liabilities stood at $28.9 billion in 2022, then decreased by 5.98% to $27.2 billion in 2023, then slipped by 15.99% to $22.9 billion in 2024, then retreated by 1.68% to $22.5 billion in 2025, then slipped by 1.36% to $22.2 billion in 2026.
- Business Quant data shows VTRS's Total Liabilities at $22.2 billion in Q1 2026, $22.5 billion in Q4 2025, and $22.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.12 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 2.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.78 Bn |
| Mar 31, 2026 | 22.18 Bn |
| Dec 31, 2025 | 22.48 Bn |
| Sep 30, 2025 | 22.70 Bn |
| Jun 30, 2025 | 22.84 Bn |
| Mar 31, 2025 | 22.82 Bn |
| Dec 31, 2024 | 22.87 Bn |
| Sep 30, 2024 | 24.96 Bn |
| Jun 30, 2024 | 25.81 Bn |
| Mar 31, 2024 | 27.33 Bn |
| Dec 31, 2023 | 27.22 Bn |
| Sep 30, 2023 | 27.88 Bn |
| Jun 30, 2023 | 27.85 Bn |
| Mar 31, 2023 | 28.36 Bn |
| Dec 31, 2022 | 28.95 Bn |
| Sep 30, 2022 | 29.48 Bn |
| Jun 30, 2022 | 31.32 Bn |
| Mar 31, 2022 | 33.02 Bn |
| Dec 31, 2021 | 34.35 Bn |
| Sep 30, 2021 | 34.93 Bn |